Xeris Biopharma Holdings Stock (NASDAQ:XERS), Analyst Ratings, Price Targets, Predictions

The latest price target for Xeris Biopharma Holdings (NASDAQ: XERS) was reported by Piper Sandler on May 10, 2024. The analyst firm set a price target for $3.00 expecting XERS to rise to within 12 months (a possible 70.44% upside). 7 analyst firms have reported ratings in the last year.

The latest analyst rating for Xeris Biopharma Holdings (NASDAQ: XERS) was provided by Piper Sandler, and Xeris Biopharma Holdings reiterated their overweight rating.

There is no last upgrade for Xeris Biopharma Holdings.

There is no last downgrade for Xeris Biopharma Holdings.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Xeris Biopharma Holdings, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Xeris Biopharma Holdings was filed on May 10, 2024 so you should expect the next rating to be made available sometime around May 10, 2025.

While ratings are subjective and will change, the latest Xeris Biopharma Holdings (XERS) rating was a reiterated with a price target of $4.00 to $3.00. The current price Xeris Biopharma Holdings (XERS) is trading at is $1.76, which is out of the analyst’s predicted range.